nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Cladribine—Floxuridine—stomach cancer	0.786	1	CrCrCtD
Regadenoson—Adenosine monophosphate—PRKAB1—stomach cancer	0.00234	0.218	CrCbGaD
Regadenoson—Adenosine monophosphate—FBP1—stomach cancer	0.00234	0.218	CrCbGaD
Regadenoson—Cytarabine—NT5E—stomach cancer	0.00197	0.183	CrCbGaD
Regadenoson—Azacitidine—DNMT1—stomach cancer	0.00158	0.147	CrCbGaD
Regadenoson—Adenosine monophosphate—PRKAA1—stomach cancer	0.00135	0.125	CrCbGaD
Regadenoson—Adenosine triphosphate—PRKAA1—stomach cancer	0.00117	0.109	CrCbGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—TWIST1—stomach cancer	0.000928	0.0955	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—ID4—stomach cancer	0.000459	0.0472	CbGpPWpGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—APEX1—stomach cancer	0.00036	0.037	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Other—HRH4—stomach cancer	0.000359	0.0369	CbGpPWpGaD
Regadenoson—Abdominal distension—Doxorubicin—stomach cancer	0.000271	0.0014	CcSEcCtD
Regadenoson—Ill-defined disorder—Capecitabine—stomach cancer	0.00027	0.00139	CcSEcCtD
Regadenoson—Urticaria—Fluorouracil—stomach cancer	0.00027	0.00139	CcSEcCtD
Regadenoson—Syncope—Docetaxel—stomach cancer	0.00027	0.00139	CcSEcCtD
Regadenoson—Asthma—Doxorubicin—stomach cancer	0.000269	0.00139	CcSEcCtD
Regadenoson—Palpitations—Docetaxel—stomach cancer	0.000266	0.00137	CcSEcCtD
Regadenoson—Loss of consciousness—Docetaxel—stomach cancer	0.000264	0.00136	CcSEcCtD
Regadenoson—Malaise—Capecitabine—stomach cancer	0.000262	0.00135	CcSEcCtD
Regadenoson—Cough—Docetaxel—stomach cancer	0.000262	0.00135	CcSEcCtD
Regadenoson—Angina pectoris—Doxorubicin—stomach cancer	0.000262	0.00135	CcSEcCtD
Regadenoson—Hypersensitivity—Irinotecan—stomach cancer	0.000261	0.00135	CcSEcCtD
Regadenoson—Syncope—Capecitabine—stomach cancer	0.000261	0.00135	CcSEcCtD
Regadenoson—Convulsion—Docetaxel—stomach cancer	0.00026	0.00134	CcSEcCtD
Regadenoson—Hypertension—Docetaxel—stomach cancer	0.000259	0.00134	CcSEcCtD
Regadenoson—Palpitations—Capecitabine—stomach cancer	0.000257	0.00133	CcSEcCtD
Regadenoson—Chest pain—Docetaxel—stomach cancer	0.000256	0.00132	CcSEcCtD
Regadenoson—Arthralgia—Docetaxel—stomach cancer	0.000256	0.00132	CcSEcCtD
Regadenoson—Myalgia—Docetaxel—stomach cancer	0.000256	0.00132	CcSEcCtD
Regadenoson—Loss of consciousness—Capecitabine—stomach cancer	0.000256	0.00132	CcSEcCtD
Regadenoson—Renal failure—Epirubicin—stomach cancer	0.000255	0.00131	CcSEcCtD
Regadenoson—Asthenia—Irinotecan—stomach cancer	0.000255	0.00131	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—stomach cancer	0.000254	0.00131	CcSEcCtD
Regadenoson—Cough—Capecitabine—stomach cancer	0.000254	0.00131	CcSEcCtD
Regadenoson—Hypertension—Capecitabine—stomach cancer	0.000251	0.0013	CcSEcCtD
Regadenoson—Hypersensitivity—Fluorouracil—stomach cancer	0.00025	0.00129	CcSEcCtD
Regadenoson—Myalgia—Capecitabine—stomach cancer	0.000248	0.00128	CcSEcCtD
Regadenoson—Chest pain—Capecitabine—stomach cancer	0.000248	0.00128	CcSEcCtD
Regadenoson—Arthralgia—Capecitabine—stomach cancer	0.000248	0.00128	CcSEcCtD
Regadenoson—Anxiety—Capecitabine—stomach cancer	0.000247	0.00127	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	0.000246	0.00127	CcSEcCtD
Regadenoson—Anaphylactic shock—Docetaxel—stomach cancer	0.000245	0.00126	CcSEcCtD
Regadenoson—Discomfort—Capecitabine—stomach cancer	0.000245	0.00126	CcSEcCtD
Regadenoson—Diarrhoea—Irinotecan—stomach cancer	0.000243	0.00125	CcSEcCtD
Regadenoson—Shock—Docetaxel—stomach cancer	0.000241	0.00124	CcSEcCtD
Regadenoson—Nervous system disorder—Docetaxel—stomach cancer	0.000241	0.00124	CcSEcCtD
Regadenoson—Tachycardia—Docetaxel—stomach cancer	0.000239	0.00123	CcSEcCtD
Regadenoson—Skin disorder—Docetaxel—stomach cancer	0.000238	0.00123	CcSEcCtD
Regadenoson—Bradycardia—Epirubicin—stomach cancer	0.000237	0.00122	CcSEcCtD
Regadenoson—Renal failure—Doxorubicin—stomach cancer	0.000236	0.00122	CcSEcCtD
Regadenoson—Dizziness—Irinotecan—stomach cancer	0.000235	0.00121	CcSEcCtD
Regadenoson—Shock—Capecitabine—stomach cancer	0.000234	0.0012	CcSEcCtD
Regadenoson—Nervous system disorder—Capecitabine—stomach cancer	0.000233	0.0012	CcSEcCtD
Regadenoson—Eye disorder—Methotrexate—stomach cancer	0.000233	0.0012	CcSEcCtD
Regadenoson—Diarrhoea—Fluorouracil—stomach cancer	0.000233	0.0012	CcSEcCtD
Regadenoson—Tinnitus—Methotrexate—stomach cancer	0.000232	0.0012	CcSEcCtD
Regadenoson—Tachycardia—Capecitabine—stomach cancer	0.000232	0.0012	CcSEcCtD
Regadenoson—Hypoaesthesia—Epirubicin—stomach cancer	0.000232	0.00119	CcSEcCtD
Regadenoson—Cardiac disorder—Methotrexate—stomach cancer	0.000231	0.00119	CcSEcCtD
Regadenoson—Skin disorder—Capecitabine—stomach cancer	0.000231	0.00119	CcSEcCtD
Regadenoson—Hyperhidrosis—Capecitabine—stomach cancer	0.00023	0.00118	CcSEcCtD
Regadenoson—Hypotension—Docetaxel—stomach cancer	0.000229	0.00118	CcSEcCtD
Regadenoson—Connective tissue disorder—Epirubicin—stomach cancer	0.000229	0.00118	CcSEcCtD
Regadenoson—Angiopathy—Methotrexate—stomach cancer	0.000226	0.00116	CcSEcCtD
Regadenoson—Vomiting—Irinotecan—stomach cancer	0.000226	0.00116	CcSEcCtD
Regadenoson—Immune system disorder—Methotrexate—stomach cancer	0.000225	0.00116	CcSEcCtD
Regadenoson—Dizziness—Fluorouracil—stomach cancer	0.000225	0.00116	CcSEcCtD
Regadenoson—Mediastinal disorder—Methotrexate—stomach cancer	0.000224	0.00116	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—KMT2A—stomach cancer	0.000224	0.023	CbGpPWpGaD
Regadenoson—Rash—Irinotecan—stomach cancer	0.000224	0.00115	CcSEcCtD
Regadenoson—Dermatitis—Irinotecan—stomach cancer	0.000224	0.00115	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Docetaxel—stomach cancer	0.000223	0.00115	CcSEcCtD
Regadenoson—Headache—Irinotecan—stomach cancer	0.000222	0.00115	CcSEcCtD
Regadenoson—Hypotension—Capecitabine—stomach cancer	0.000222	0.00114	CcSEcCtD
Regadenoson—Insomnia—Docetaxel—stomach cancer	0.000222	0.00114	CcSEcCtD
Regadenoson—Paraesthesia—Docetaxel—stomach cancer	0.00022	0.00114	CcSEcCtD
Regadenoson—Bradycardia—Doxorubicin—stomach cancer	0.000219	0.00113	CcSEcCtD
Regadenoson—Dyspnoea—Docetaxel—stomach cancer	0.000219	0.00113	CcSEcCtD
Regadenoson—Somnolence—Docetaxel—stomach cancer	0.000218	0.00112	CcSEcCtD
Regadenoson—Mental disorder—Methotrexate—stomach cancer	0.000218	0.00112	CcSEcCtD
Regadenoson—Eye disorder—Epirubicin—stomach cancer	0.000218	0.00112	CcSEcCtD
Regadenoson—Tinnitus—Epirubicin—stomach cancer	0.000217	0.00112	CcSEcCtD
Regadenoson—Erythema—Methotrexate—stomach cancer	0.000217	0.00112	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Capecitabine—stomach cancer	0.000216	0.00112	CcSEcCtD
Regadenoson—Cardiac disorder—Epirubicin—stomach cancer	0.000216	0.00111	CcSEcCtD
Regadenoson—Flushing—Epirubicin—stomach cancer	0.000216	0.00111	CcSEcCtD
Regadenoson—Vomiting—Fluorouracil—stomach cancer	0.000216	0.00111	CcSEcCtD
Regadenoson—Insomnia—Capecitabine—stomach cancer	0.000215	0.00111	CcSEcCtD
Regadenoson—Hypoaesthesia—Doxorubicin—stomach cancer	0.000214	0.00111	CcSEcCtD
Regadenoson—Rash—Fluorouracil—stomach cancer	0.000214	0.0011	CcSEcCtD
Regadenoson—Dermatitis—Fluorouracil—stomach cancer	0.000214	0.0011	CcSEcCtD
Regadenoson—Paraesthesia—Capecitabine—stomach cancer	0.000213	0.0011	CcSEcCtD
Regadenoson—Headache—Fluorouracil—stomach cancer	0.000213	0.0011	CcSEcCtD
Regadenoson—Dysgeusia—Methotrexate—stomach cancer	0.000212	0.00109	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Docetaxel—stomach cancer	0.000212	0.00109	CcSEcCtD
Regadenoson—Connective tissue disorder—Doxorubicin—stomach cancer	0.000212	0.00109	CcSEcCtD
Regadenoson—Dyspnoea—Capecitabine—stomach cancer	0.000212	0.00109	CcSEcCtD
Regadenoson—Angiopathy—Epirubicin—stomach cancer	0.000211	0.00109	CcSEcCtD
Regadenoson—Nausea—Irinotecan—stomach cancer	0.000211	0.00109	CcSEcCtD
Regadenoson—Immune system disorder—Epirubicin—stomach cancer	0.00021	0.00108	CcSEcCtD
Regadenoson—Mediastinal disorder—Epirubicin—stomach cancer	0.00021	0.00108	CcSEcCtD
Regadenoson—Pain—Docetaxel—stomach cancer	0.00021	0.00108	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Other—F2R—stomach cancer	0.000206	0.0212	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Capecitabine—stomach cancer	0.000205	0.00106	CcSEcCtD
Regadenoson—Vision blurred—Methotrexate—stomach cancer	0.000204	0.00105	CcSEcCtD
Regadenoson—Mental disorder—Epirubicin—stomach cancer	0.000204	0.00105	CcSEcCtD
Regadenoson—Pain—Capecitabine—stomach cancer	0.000203	0.00105	CcSEcCtD
Regadenoson—Erythema—Epirubicin—stomach cancer	0.000203	0.00105	CcSEcCtD
Regadenoson—Feeling abnormal—Docetaxel—stomach cancer	0.000202	0.00104	CcSEcCtD
Regadenoson—Nausea—Fluorouracil—stomach cancer	0.000202	0.00104	CcSEcCtD
Regadenoson—Eye disorder—Doxorubicin—stomach cancer	0.000201	0.00104	CcSEcCtD
Regadenoson—Ill-defined disorder—Methotrexate—stomach cancer	0.000201	0.00104	CcSEcCtD
Regadenoson—Tinnitus—Doxorubicin—stomach cancer	0.000201	0.00104	CcSEcCtD
Regadenoson—Gastrointestinal pain—Docetaxel—stomach cancer	0.000201	0.00103	CcSEcCtD
Regadenoson—Cardiac disorder—Doxorubicin—stomach cancer	0.0002	0.00103	CcSEcCtD
Regadenoson—Flushing—Doxorubicin—stomach cancer	0.0002	0.00103	CcSEcCtD
Regadenoson—Dysgeusia—Epirubicin—stomach cancer	0.000199	0.00102	CcSEcCtD
Regadenoson—Feeling abnormal—Capecitabine—stomach cancer	0.000196	0.00101	CcSEcCtD
Regadenoson—Angiopathy—Doxorubicin—stomach cancer	0.000195	0.00101	CcSEcCtD
Regadenoson—Malaise—Methotrexate—stomach cancer	0.000195	0.00101	CcSEcCtD
Regadenoson—Immune system disorder—Doxorubicin—stomach cancer	0.000195	0.001	CcSEcCtD
Regadenoson—Gastrointestinal pain—Capecitabine—stomach cancer	0.000194	0.001	CcSEcCtD
Regadenoson—Mediastinal disorder—Doxorubicin—stomach cancer	0.000194	0.001	CcSEcCtD
Regadenoson—Abdominal pain—Docetaxel—stomach cancer	0.000194	0.001	CcSEcCtD
Regadenoson—Vision blurred—Epirubicin—stomach cancer	0.000191	0.000985	CcSEcCtD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—SERPINE1—stomach cancer	0.000191	0.0196	CbGpPWpGaD
Regadenoson—Cough—Methotrexate—stomach cancer	0.000189	0.000975	CcSEcCtD
Regadenoson—Mental disorder—Doxorubicin—stomach cancer	0.000189	0.000973	CcSEcCtD
Regadenoson—Urticaria—Capecitabine—stomach cancer	0.000189	0.000973	CcSEcCtD
Regadenoson—Ill-defined disorder—Epirubicin—stomach cancer	0.000188	0.00097	CcSEcCtD
Regadenoson—Abdominal pain—Capecitabine—stomach cancer	0.000188	0.000968	CcSEcCtD
Regadenoson—Convulsion—Methotrexate—stomach cancer	0.000188	0.000968	CcSEcCtD
Regadenoson—Erythema—Doxorubicin—stomach cancer	0.000188	0.000967	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—KISS1R—stomach cancer	0.000185	0.019	CbGpPWpGaD
Regadenoson—Myalgia—Methotrexate—stomach cancer	0.000184	0.000951	CcSEcCtD
Regadenoson—Chest pain—Methotrexate—stomach cancer	0.000184	0.000951	CcSEcCtD
Regadenoson—Arthralgia—Methotrexate—stomach cancer	0.000184	0.000951	CcSEcCtD
Regadenoson—Dysgeusia—Doxorubicin—stomach cancer	0.000184	0.000947	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	0.000183	0.000944	CcSEcCtD
Regadenoson—Malaise—Epirubicin—stomach cancer	0.000183	0.000943	CcSEcCtD
Regadenoson—Discomfort—Methotrexate—stomach cancer	0.000182	0.000939	CcSEcCtD
Regadenoson—Syncope—Epirubicin—stomach cancer	0.000182	0.000937	CcSEcCtD
Regadenoson—Hypersensitivity—Docetaxel—stomach cancer	0.000181	0.000932	CcSEcCtD
Regadenoson—Palpitations—Epirubicin—stomach cancer	0.000179	0.000924	CcSEcCtD
Regadenoson—Loss of consciousness—Epirubicin—stomach cancer	0.000178	0.000919	CcSEcCtD
Regadenoson—Cough—Epirubicin—stomach cancer	0.000177	0.000912	CcSEcCtD
Regadenoson—Anaphylactic shock—Methotrexate—stomach cancer	0.000177	0.000912	CcSEcCtD
Regadenoson—Vision blurred—Doxorubicin—stomach cancer	0.000177	0.000911	CcSEcCtD
Regadenoson—Asthenia—Docetaxel—stomach cancer	0.000176	0.000907	CcSEcCtD
Regadenoson—Convulsion—Epirubicin—stomach cancer	0.000176	0.000906	CcSEcCtD
Regadenoson—Hypertension—Epirubicin—stomach cancer	0.000175	0.000902	CcSEcCtD
Regadenoson—Hypersensitivity—Capecitabine—stomach cancer	0.000175	0.000902	CcSEcCtD
Regadenoson—Ill-defined disorder—Doxorubicin—stomach cancer	0.000174	0.000897	CcSEcCtD
Regadenoson—Nervous system disorder—Methotrexate—stomach cancer	0.000173	0.000894	CcSEcCtD
Regadenoson—Myalgia—Epirubicin—stomach cancer	0.000173	0.00089	CcSEcCtD
Regadenoson—Chest pain—Epirubicin—stomach cancer	0.000173	0.00089	CcSEcCtD
Regadenoson—Arthralgia—Epirubicin—stomach cancer	0.000173	0.00089	CcSEcCtD
Regadenoson—Anxiety—Epirubicin—stomach cancer	0.000172	0.000887	CcSEcCtD
Regadenoson—Skin disorder—Methotrexate—stomach cancer	0.000172	0.000885	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	0.000171	0.000884	CcSEcCtD
Regadenoson—Hyperhidrosis—Methotrexate—stomach cancer	0.000171	0.000881	CcSEcCtD
Regadenoson—Discomfort—Epirubicin—stomach cancer	0.000171	0.000879	CcSEcCtD
Regadenoson—Asthenia—Capecitabine—stomach cancer	0.00017	0.000879	CcSEcCtD
Regadenoson—Malaise—Doxorubicin—stomach cancer	0.000169	0.000872	CcSEcCtD
Regadenoson—Syncope—Doxorubicin—stomach cancer	0.000168	0.000867	CcSEcCtD
Regadenoson—Diarrhoea—Docetaxel—stomach cancer	0.000168	0.000865	CcSEcCtD
Regadenoson—Palpitations—Doxorubicin—stomach cancer	0.000166	0.000855	CcSEcCtD
Regadenoson—Anaphylactic shock—Epirubicin—stomach cancer	0.000165	0.000853	CcSEcCtD
Regadenoson—Hypotension—Methotrexate—stomach cancer	0.000165	0.000852	CcSEcCtD
Regadenoson—Loss of consciousness—Doxorubicin—stomach cancer	0.000165	0.00085	CcSEcCtD
Regadenoson—Cough—Doxorubicin—stomach cancer	0.000164	0.000844	CcSEcCtD
Regadenoson—Shock—Epirubicin—stomach cancer	0.000163	0.000839	CcSEcCtD
Regadenoson—ADORA2A—Monoamine Transport—IL1B—stomach cancer	0.000163	0.0167	CbGpPWpGaD
Regadenoson—Convulsion—Doxorubicin—stomach cancer	0.000163	0.000838	CcSEcCtD
Regadenoson—Diarrhoea—Capecitabine—stomach cancer	0.000162	0.000838	CcSEcCtD
Regadenoson—Nervous system disorder—Epirubicin—stomach cancer	0.000162	0.000837	CcSEcCtD
Regadenoson—Dizziness—Docetaxel—stomach cancer	0.000162	0.000836	CcSEcCtD
Regadenoson—Hypertension—Doxorubicin—stomach cancer	0.000162	0.000835	CcSEcCtD
Regadenoson—Tachycardia—Epirubicin—stomach cancer	0.000161	0.000833	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Methotrexate—stomach cancer	0.000161	0.00083	CcSEcCtD
Regadenoson—Skin disorder—Epirubicin—stomach cancer	0.000161	0.000829	CcSEcCtD
Regadenoson—Hyperhidrosis—Epirubicin—stomach cancer	0.00016	0.000825	CcSEcCtD
Regadenoson—Insomnia—Methotrexate—stomach cancer	0.00016	0.000824	CcSEcCtD
Regadenoson—Myalgia—Doxorubicin—stomach cancer	0.00016	0.000823	CcSEcCtD
Regadenoson—Chest pain—Doxorubicin—stomach cancer	0.00016	0.000823	CcSEcCtD
Regadenoson—Arthralgia—Doxorubicin—stomach cancer	0.00016	0.000823	CcSEcCtD
Regadenoson—Anxiety—Doxorubicin—stomach cancer	0.000159	0.000821	CcSEcCtD
Regadenoson—Paraesthesia—Methotrexate—stomach cancer	0.000159	0.000818	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	0.000159	0.000818	CcSEcCtD
Regadenoson—Discomfort—Doxorubicin—stomach cancer	0.000158	0.000813	CcSEcCtD
Regadenoson—Dyspnoea—Methotrexate—stomach cancer	0.000158	0.000813	CcSEcCtD
Regadenoson—Somnolence—Methotrexate—stomach cancer	0.000157	0.00081	CcSEcCtD
Regadenoson—Dizziness—Capecitabine—stomach cancer	0.000157	0.00081	CcSEcCtD
Regadenoson—Vomiting—Docetaxel—stomach cancer	0.000156	0.000804	CcSEcCtD
Regadenoson—Rash—Docetaxel—stomach cancer	0.000155	0.000797	CcSEcCtD
Regadenoson—Hypotension—Epirubicin—stomach cancer	0.000155	0.000797	CcSEcCtD
Regadenoson—Dermatitis—Docetaxel—stomach cancer	0.000155	0.000797	CcSEcCtD
Regadenoson—Headache—Docetaxel—stomach cancer	0.000154	0.000792	CcSEcCtD
Regadenoson—Anaphylactic shock—Doxorubicin—stomach cancer	0.000153	0.000789	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Methotrexate—stomach cancer	0.000153	0.000787	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Other—ADRB2—stomach cancer	0.000152	0.0157	CbGpPWpGaD
Regadenoson—Pain—Methotrexate—stomach cancer	0.000151	0.000779	CcSEcCtD
Regadenoson—Vomiting—Capecitabine—stomach cancer	0.000151	0.000779	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Epirubicin—stomach cancer	0.000151	0.000777	CcSEcCtD
Regadenoson—Shock—Doxorubicin—stomach cancer	0.000151	0.000777	CcSEcCtD
Regadenoson—Nervous system disorder—Doxorubicin—stomach cancer	0.00015	0.000774	CcSEcCtD
Regadenoson—Rash—Capecitabine—stomach cancer	0.00015	0.000772	CcSEcCtD
Regadenoson—Insomnia—Epirubicin—stomach cancer	0.00015	0.000772	CcSEcCtD
Regadenoson—Dermatitis—Capecitabine—stomach cancer	0.00015	0.000771	CcSEcCtD
Regadenoson—Tachycardia—Doxorubicin—stomach cancer	0.000149	0.00077	CcSEcCtD
Regadenoson—Headache—Capecitabine—stomach cancer	0.000149	0.000767	CcSEcCtD
Regadenoson—Skin disorder—Doxorubicin—stomach cancer	0.000149	0.000767	CcSEcCtD
Regadenoson—Paraesthesia—Epirubicin—stomach cancer	0.000149	0.000766	CcSEcCtD
Regadenoson—Hyperhidrosis—Doxorubicin—stomach cancer	0.000148	0.000763	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—RORA—stomach cancer	0.000148	0.0152	CbGpPWpGaD
Regadenoson—Dyspnoea—Epirubicin—stomach cancer	0.000148	0.000761	CcSEcCtD
Regadenoson—Somnolence—Epirubicin—stomach cancer	0.000147	0.000758	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—ADRB1—stomach cancer	0.000147	0.0151	CbGpPWpGaD
Regadenoson—Nausea—Docetaxel—stomach cancer	0.000146	0.000751	CcSEcCtD
Regadenoson—Feeling abnormal—Methotrexate—stomach cancer	0.000146	0.000751	CcSEcCtD
Regadenoson—Gastrointestinal pain—Methotrexate—stomach cancer	0.000145	0.000745	CcSEcCtD
Regadenoson—Hypotension—Doxorubicin—stomach cancer	0.000143	0.000738	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Epirubicin—stomach cancer	0.000143	0.000736	CcSEcCtD
Regadenoson—Pain—Epirubicin—stomach cancer	0.000141	0.000729	CcSEcCtD
Regadenoson—Nausea—Capecitabine—stomach cancer	0.000141	0.000727	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—KISS1R—stomach cancer	0.000141	0.0145	CbGpPWpGaD
Regadenoson—Urticaria—Methotrexate—stomach cancer	0.00014	0.000724	CcSEcCtD
Regadenoson—Abdominal pain—Methotrexate—stomach cancer	0.00014	0.000721	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Doxorubicin—stomach cancer	0.000139	0.000719	CcSEcCtD
Regadenoson—Insomnia—Doxorubicin—stomach cancer	0.000138	0.000714	CcSEcCtD
Regadenoson—Paraesthesia—Doxorubicin—stomach cancer	0.000137	0.000709	CcSEcCtD
Regadenoson—Dyspnoea—Doxorubicin—stomach cancer	0.000136	0.000704	CcSEcCtD
Regadenoson—Feeling abnormal—Epirubicin—stomach cancer	0.000136	0.000703	CcSEcCtD
Regadenoson—Somnolence—Doxorubicin—stomach cancer	0.000136	0.000702	CcSEcCtD
Regadenoson—Gastrointestinal pain—Epirubicin—stomach cancer	0.000135	0.000698	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—HRH4—stomach cancer	0.000134	0.0137	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PRKAA1—stomach cancer	0.000133	0.0137	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.000132	0.000681	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—AHR—stomach cancer	0.000132	0.0136	CbGpPWpGaD
Regadenoson—Urticaria—Epirubicin—stomach cancer	0.000131	0.000678	CcSEcCtD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—stomach cancer	0.000131	0.0135	CbGpPWpGaD
Regadenoson—Pain—Doxorubicin—stomach cancer	0.000131	0.000675	CcSEcCtD
Regadenoson—Abdominal pain—Epirubicin—stomach cancer	0.000131	0.000674	CcSEcCtD
Regadenoson—Hypersensitivity—Methotrexate—stomach cancer	0.00013	0.000672	CcSEcCtD
Regadenoson—Asthenia—Methotrexate—stomach cancer	0.000127	0.000654	CcSEcCtD
Regadenoson—Feeling abnormal—Doxorubicin—stomach cancer	0.000126	0.00065	CcSEcCtD
Regadenoson—Gastrointestinal pain—Doxorubicin—stomach cancer	0.000125	0.000645	CcSEcCtD
Regadenoson—Hypersensitivity—Epirubicin—stomach cancer	0.000122	0.000628	CcSEcCtD
Regadenoson—Urticaria—Doxorubicin—stomach cancer	0.000122	0.000627	CcSEcCtD
Regadenoson—Abdominal pain—Doxorubicin—stomach cancer	0.000121	0.000624	CcSEcCtD
Regadenoson—Diarrhoea—Methotrexate—stomach cancer	0.000121	0.000624	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—KISS1—stomach cancer	0.000119	0.0123	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—ADRB2—stomach cancer	0.000119	0.0122	CbGpPWpGaD
Regadenoson—Asthenia—Epirubicin—stomach cancer	0.000119	0.000612	CcSEcCtD
Regadenoson—ADORA2A—Monoamine Transport—TNF—stomach cancer	0.000118	0.0121	CbGpPWpGaD
Regadenoson—Dizziness—Methotrexate—stomach cancer	0.000117	0.000603	CcSEcCtD
Regadenoson—Diarrhoea—Epirubicin—stomach cancer	0.000113	0.000584	CcSEcCtD
Regadenoson—Hypersensitivity—Doxorubicin—stomach cancer	0.000113	0.000582	CcSEcCtD
Regadenoson—Vomiting—Methotrexate—stomach cancer	0.000112	0.00058	CcSEcCtD
Regadenoson—Rash—Methotrexate—stomach cancer	0.000111	0.000575	CcSEcCtD
Regadenoson—Dermatitis—Methotrexate—stomach cancer	0.000111	0.000574	CcSEcCtD
Regadenoson—Headache—Methotrexate—stomach cancer	0.000111	0.000571	CcSEcCtD
Regadenoson—Asthenia—Doxorubicin—stomach cancer	0.00011	0.000566	CcSEcCtD
Regadenoson—Dizziness—Epirubicin—stomach cancer	0.000109	0.000564	CcSEcCtD
Regadenoson—Vomiting—Epirubicin—stomach cancer	0.000105	0.000542	CcSEcCtD
Regadenoson—Nausea—Methotrexate—stomach cancer	0.000105	0.000541	CcSEcCtD
Regadenoson—Diarrhoea—Doxorubicin—stomach cancer	0.000105	0.00054	CcSEcCtD
Regadenoson—Rash—Epirubicin—stomach cancer	0.000104	0.000538	CcSEcCtD
Regadenoson—Dermatitis—Epirubicin—stomach cancer	0.000104	0.000537	CcSEcCtD
Regadenoson—Headache—Epirubicin—stomach cancer	0.000104	0.000534	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—HRH4—stomach cancer	0.000102	0.0105	CbGpPWpGaD
Regadenoson—Dizziness—Doxorubicin—stomach cancer	0.000101	0.000522	CcSEcCtD
Regadenoson—Nausea—Epirubicin—stomach cancer	9.83e-05	0.000507	CcSEcCtD
Regadenoson—Vomiting—Doxorubicin—stomach cancer	9.73e-05	0.000502	CcSEcCtD
Regadenoson—Rash—Doxorubicin—stomach cancer	9.65e-05	0.000498	CcSEcCtD
Regadenoson—Dermatitis—Doxorubicin—stomach cancer	9.64e-05	0.000497	CcSEcCtD
Regadenoson—Headache—Doxorubicin—stomach cancer	9.59e-05	0.000494	CcSEcCtD
Regadenoson—Nausea—Doxorubicin—stomach cancer	9.09e-05	0.000469	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—KISS1—stomach cancer	9.07e-05	0.00933	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—AGTR2—stomach cancer	9.06e-05	0.00932	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—F2R—stomach cancer	8.96e-05	0.00922	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—HTR1A—stomach cancer	8.72e-05	0.00897	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—HBEGF—stomach cancer	8.58e-05	0.00882	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—ADRB1—stomach cancer	8.16e-05	0.00839	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—KISS1R—stomach cancer	7.96e-05	0.00818	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AGTR2—stomach cancer	7.76e-05	0.00799	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PPP2R1A—stomach cancer	7.76e-05	0.00798	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—F2R—stomach cancer	7.68e-05	0.0079	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—HTR1A—stomach cancer	7.47e-05	0.00769	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—KISS1R—stomach cancer	7.23e-05	0.00743	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ANXA1—stomach cancer	7.22e-05	0.00742	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—TYMS—stomach cancer	7.21e-05	0.00742	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRB1—stomach cancer	6.99e-05	0.00719	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FYN—stomach cancer	6.84e-05	0.00703	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—ADRB2—stomach cancer	6.61e-05	0.0068	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—HBEGF—stomach cancer	6.6e-05	0.00678	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGFR2—stomach cancer	6.42e-05	0.0066	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PPP2R1A—stomach cancer	5.97e-05	0.00614	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—AGTR2—stomach cancer	5.91e-05	0.00608	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IRS2—stomach cancer	5.88e-05	0.00605	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—F2R—stomach cancer	5.85e-05	0.00601	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—HRH4—stomach cancer	5.75e-05	0.00592	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—HTR1A—stomach cancer	5.69e-05	0.00585	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—stomach cancer	5.66e-05	0.00583	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—CDK4—stomach cancer	5.62e-05	0.00579	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—ANXA1—stomach cancer	5.5e-05	0.00565	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6ST—stomach cancer	5.4e-05	0.00556	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—ADRB1—stomach cancer	5.32e-05	0.00548	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—FYN—stomach cancer	5.26e-05	0.00541	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HRH4—stomach cancer	5.22e-05	0.00537	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—KISS1—stomach cancer	5.13e-05	0.00527	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PPARG—stomach cancer	5.11e-05	0.00526	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—FGFR2—stomach cancer	4.94e-05	0.00508	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6R—stomach cancer	4.82e-05	0.00496	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—KISS1—stomach cancer	4.66e-05	0.00479	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—SERPINE1—stomach cancer	4.6e-05	0.00474	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IRS2—stomach cancer	4.52e-05	0.00465	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GAST—stomach cancer	4.41e-05	0.00453	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—RGS2—stomach cancer	4.41e-05	0.00453	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—RHOA—stomach cancer	4.35e-05	0.00448	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—ADRB2—stomach cancer	4.31e-05	0.00444	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KISS1R—stomach cancer	4.27e-05	0.00439	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GLI3—stomach cancer	4.27e-05	0.00439	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IL6ST—stomach cancer	4.16e-05	0.00427	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RBP1—stomach cancer	4.07e-05	0.00419	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—stomach cancer	4.03e-05	0.00415	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GAST—stomach cancer	4e-05	0.00412	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—RGS2—stomach cancer	4e-05	0.00412	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1B—stomach cancer	3.73e-05	0.00384	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IL6R—stomach cancer	3.71e-05	0.00381	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—JUN—stomach cancer	3.62e-05	0.00373	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1A—stomach cancer	3.45e-05	0.00354	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—MAPK8—stomach cancer	3.43e-05	0.00353	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—RHOA—stomach cancer	3.35e-05	0.00344	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AGTR2—stomach cancer	3.34e-05	0.00344	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—WWOX—stomach cancer	3.32e-05	0.00341	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—F2R—stomach cancer	3.3e-05	0.0034	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—HTR1A—stomach cancer	3.22e-05	0.00331	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ANXA1—stomach cancer	3.11e-05	0.00319	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—ERBB2—stomach cancer	3.1e-05	0.00319	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—WIF1—stomach cancer	3.09e-05	0.00317	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HRH4—stomach cancer	3.09e-05	0.00317	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—stomach cancer	3.07e-05	0.00316	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AGTR2—stomach cancer	3.03e-05	0.00312	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADRB1—stomach cancer	3.01e-05	0.00309	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—F2R—stomach cancer	3e-05	0.00309	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK3—stomach cancer	2.94e-05	0.00302	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HTR1A—stomach cancer	2.92e-05	0.003	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CDKN1B—stomach cancer	2.87e-05	0.00295	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKAB1—stomach cancer	2.85e-05	0.00293	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ANXA1—stomach cancer	2.82e-05	0.0029	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK1—stomach cancer	2.79e-05	0.00287	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—stomach cancer	2.79e-05	0.00287	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KISS1—stomach cancer	2.75e-05	0.00283	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RNF43—stomach cancer	2.75e-05	0.00283	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—stomach cancer	2.74e-05	0.00281	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADRB1—stomach cancer	2.73e-05	0.00281	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CDKN1A—stomach cancer	2.65e-05	0.00273	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—stomach cancer	2.64e-05	0.00271	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAPK8—stomach cancer	2.59e-05	0.00266	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FST—stomach cancer	2.45e-05	0.00252	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADRB2—stomach cancer	2.44e-05	0.00251	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—stomach cancer	2.43e-05	0.00249	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HBEGF—stomach cancer	2.4e-05	0.00247	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—TP53—stomach cancer	2.39e-05	0.00246	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RGS2—stomach cancer	2.37e-05	0.00243	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GAST—stomach cancer	2.37e-05	0.00243	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—STAT3—stomach cancer	2.36e-05	0.00243	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAPK3—stomach cancer	2.26e-05	0.00232	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—stomach cancer	2.24e-05	0.00231	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGG—stomach cancer	2.24e-05	0.00231	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADRB2—stomach cancer	2.21e-05	0.00228	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—IL6—stomach cancer	2.19e-05	0.00225	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PPP2R1A—stomach cancer	2.17e-05	0.00223	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKAA1—stomach cancer	2.16e-05	0.00222	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAPK1—stomach cancer	2.15e-05	0.00221	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—EGFR—stomach cancer	2.15e-05	0.00221	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—stomach cancer	2.15e-05	0.00221	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RBP4—stomach cancer	2.08e-05	0.00214	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CXCL8—stomach cancer	2.08e-05	0.00214	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—KRAS—stomach cancer	2.03e-05	0.00209	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CA—stomach cancer	1.87e-05	0.00192	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HSPB1—stomach cancer	1.79e-05	0.00184	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AGTR2—stomach cancer	1.79e-05	0.00184	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BMP2—stomach cancer	1.77e-05	0.00182	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—F2R—stomach cancer	1.77e-05	0.00182	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKR1C3—stomach cancer	1.74e-05	0.00179	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—HRAS—stomach cancer	1.73e-05	0.00177	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HTR1A—stomach cancer	1.73e-05	0.00177	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PRKCB—stomach cancer	1.67e-05	0.00172	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ANXA1—stomach cancer	1.67e-05	0.00171	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IL6—stomach cancer	1.65e-05	0.0017	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADRB1—stomach cancer	1.61e-05	0.00166	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RPS6—stomach cancer	1.54e-05	0.00159	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PRKCB—stomach cancer	1.52e-05	0.00156	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6ST—stomach cancer	1.51e-05	0.00155	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HBEGF—stomach cancer	1.42e-05	0.00146	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6R—stomach cancer	1.35e-05	0.00139	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—RHOA—stomach cancer	1.34e-05	0.00138	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADRB2—stomach cancer	1.31e-05	0.00134	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PPP2R1A—stomach cancer	1.28e-05	0.00132	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—RHOA—stomach cancer	1.22e-05	0.00125	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SMAD4—stomach cancer	1.19e-05	0.00122	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCL8—stomach cancer	1.18e-05	0.00121	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FYN—stomach cancer	1.13e-05	0.00116	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCL8—stomach cancer	1.07e-05	0.0011	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGFR2—stomach cancer	1.06e-05	0.00109	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IRS2—stomach cancer	9.71e-06	0.000999	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CAV1—stomach cancer	9.42e-06	0.000968	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOA1—stomach cancer	9.39e-06	0.000966	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKCB—stomach cancer	8.96e-06	0.000922	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6ST—stomach cancer	8.93e-06	0.000918	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APC—stomach cancer	8.58e-06	0.000882	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MAPK3—stomach cancer	8.21e-06	0.000845	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6R—stomach cancer	7.96e-06	0.000819	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MAPK1—stomach cancer	7.82e-06	0.000804	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EGFR—stomach cancer	7.81e-06	0.000804	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CA—stomach cancer	7.47e-06	0.000768	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SERPINE1—stomach cancer	7.46e-06	0.000767	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—KRAS—stomach cancer	7.38e-06	0.000759	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RHOA—stomach cancer	7.19e-06	0.00074	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOS3—stomach cancer	7.12e-06	0.000732	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CA—stomach cancer	6.78e-06	0.000698	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ERBB2—stomach cancer	6.66e-06	0.000685	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCL8—stomach cancer	6.32e-06	0.00065	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HRAS—stomach cancer	6.27e-06	0.000645	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN1B—stomach cancer	6.17e-06	0.000634	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6—stomach cancer	6.01e-06	0.000618	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCND1—stomach cancer	5.88e-06	0.000605	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JUN—stomach cancer	5.87e-06	0.000604	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MMP9—stomach cancer	5.71e-06	0.000587	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN1A—stomach cancer	5.69e-06	0.000585	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK8—stomach cancer	5.56e-06	0.000571	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VEGFA—stomach cancer	5.13e-06	0.000528	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—STAT3—stomach cancer	5.08e-06	0.000522	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK3—stomach cancer	4.85e-06	0.000499	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MYC—stomach cancer	4.72e-06	0.000485	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK1—stomach cancer	4.62e-06	0.000475	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EGFR—stomach cancer	4.62e-06	0.000475	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KRAS—stomach cancer	4.36e-06	0.000448	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CA—stomach cancer	4.01e-06	0.000412	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TP53—stomach cancer	3.88e-06	0.000399	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HRAS—stomach cancer	3.71e-06	0.000381	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6—stomach cancer	3.55e-06	0.000365	CbGpPWpGaD
